Globus Medical

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Globus Medical achieves record revenue, plans NuVasive merger

Globus Medical (GMED) delivered strong financial performance in 2022, with record revenue and notable growth across key segments.
The planned merger with NuVasive and focus on product innovation position the company for future success and market leadership.
Challenges such as retaining talent and addressing international market dynamics require strategic solutions for sustained growth.
Opportunities lie in diversifying revenue streams, expanding product offerings, and leveraging international markets for continued success.

Globus Medical (GMED) reports record Q1 sales, eyes growth opportunities

Globus Medical (GMED) delivered a strong Q1 performance with record sales and profit growth, driven by strategic initiatives and market demand. While facing challenges like merger delays and potential competition, the company's focus on innovation, technology leadership, and market recognition positions it well for sustained growth and success.

Globus Medical posts record Q2 sales, eyes growth through innovation

Globus Medical delivered a strong Q2 performance with record sales and profitability, driven by innovation and market expansion.
While facing integration challenges post-merger, the company's focus on growth segments and product innovation positions it well for future success.
Opportunities lie in expanding market presence, driving innovation, and capitalizing on technological advancements to sustain growth momentum.

Globus Medical reports record Q3 sales, eyes growth opportunities

Globus Medical's Q3 performance reflects robust sales growth, steady EPS, and progress towards revenue targets, underpinned by innovative product launches and strategic integration efforts.
While facing challenges in hiring and cost synergies, the company's focus on talent acquisition, cost management, and segment-specific strategies positions them well for future growth.
Opportunities lie in new product launches, technological advancements, and streamlined operations through sales force integration, indicating a promising trajectory for Globus Medical's continued success.

Globus Medical (GMED) reports record revenue in 2023, eyes growth amid challenges

Globus Medical (GMED) delivered strong financial results in 2023, driven by the NuVasive merger, with a focus on integration and innovation. While facing challenges from dissynergies and market competition, GMED is poised to capitalize on growth opportunities through strategic initiatives and product launches.

Globus Medical excels in Q1 2024, eyes Enabling Technologies growth

Globus Medical's Q1 2024 showcased exceptional sales growth, margin improvement, and strategic initiatives. Despite challenges in integration and product rollout timing, the company is poised for long-term success. Opportunities in Enabling Technologies and cost leverage position Globus for continued growth.

Globus Medical excels in Q3, eyes margin improvement strategies

Globus Medical's Q3 performance reflects strong financial results, innovation, and market expansion. While challenges in margin improvement persist, the company's strategic focus on cost optimization and product development sets the stage for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?

Globus Medical (GMED) Down 13.9% Since Last Earnings Report: Can It Rebound?

Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure

Globus Medical Reveals Positive Study Results for ExcelsiusGPS

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)

Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak

Globus Medical, Inc. (GMED) CEO Dave Demski on Q1 2019 Results - Earnings Call Transcript

Globus Medical (GMED) delivered earnings and revenue surprises of -12.20% and -1.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Globus Medical (GMED) Q1 Earnings and Revenues Miss Estimates

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Reports Next Week: What Awaits?

Globus Medical is upbeat about its growth prospects in the current and the emerging global markets through a continual expansion of direct and distributor sales forces.

Globus Medical Global Base Solid, Pricing Scenario Bothers

News for Globus Medical Stock (GMED)